New Colorectal Cancer Drug Trial Enrolls First Patients
The study evaluates an oral inhibitor for patients with advanced colorectal cancer in combination with immunotherapy.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies prioritize patient welfare when rapidly expanding new drug trials?
Vividion Therapeutics has initiated a Phase 2 trial of VVD-214, an oral inhibitor targeting Werner helicase, for the treatment of advanced colorectal cancer. The study will evaluate the drug in combination with the immunotherapy agent pembrolizumab.
Why it matters
Researchers are investigating whether targeting Werner helicase can improve treatment options for advanced colorectal cancer. This combination therapy is being tested to see if it can effectively induce DNA damage in cancer cells, potentially expanding options for patients in earlier lines of care.
The Phase 2 study (NCT07811193) will enroll approximately 140 patients across 21 countries to compare VVD-214 plus pembrolizumab against pembrolizumab alone. This represents an early-stage clinical evaluation of the combination, and outcomes remain unknown.
The players
Vividion Therapeutics
A San Diego-based biopharmaceutical company and subsidiary of Bayer AG focused on developing inhibitors for difficult-to-drug proteins.
Bayer AG
A global life sciences company that focuses on pharmaceuticals, consumer health, and agricultural products.
The details
VVD-214 functions by inhibiting the Werner helicase (WRN) enzyme. By blocking this enzyme, the drug is designed to induce lethal DNA damage in cancer cells, specifically impacting tumors that rely on WRN activity. The trial aims to determine if adding this mechanism to pembrolizumab therapy provides a clinical benefit for advanced colorectal cancer.
Timeline
2025: Phase 1a study results were presented at AACR 2025.
October 15, 2026: Announcement that the first patient was dosed in the Phase 2 trial.
Health Landscape
The study of Werner helicase inhibitors represents an emerging area in cancer therapy aimed at creating synthetic lethality in specific tumor types. This trial positions VVD-214 within the broader efforts to improve immunotherapy efficacy through combination approaches.
This drug remains in the experimental testing phase and is not currently available for general clinical use. Patients with advanced colorectal cancer interested in new trial developments should discuss ongoing clinical study participation with their oncologist.
The takeaway
The development of inhibitors targeting Werner helicase may offer a new path for managing certain colorectal cancer tumors. Patients and caregivers should keep track of trial progress, which is registered as NCT07811193, for future updates on efficacy outcomes.
Further reading
For more on the current research landscape in oncology, visit our Cancer section.
Live Poll
Do you trust that pharmaceutical companies prioritize patient welfare when rapidly expanding new drug trials?
